Clarus Therapeutics (CRXTQ) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free CRXTQ Stock Alerts $0.0010 0.00 (0.00%) (As of 03/6/2023) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineClarus Stock (NASDAQ:CLAR), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 5 at 7:30 PMClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Earnings Estimates, EPS, and Revenuebenzinga.com - October 12 at 11:19 PMClarus Therapeutics Hldgs Stock (OTC:CRXWQ), Analyst Ratings, Price Targets, Predictionsbenzinga.com - October 12 at 11:19 PMClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Codefinance.yahoo.com - September 5 at 10:33 PMClarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)finance.yahoo.com - July 28 at 11:00 AMClarus Therapeutics Holdings Inc.wsj.com - July 20 at 12:24 AMClarus Therapeutics Holdings, Inc. (CRXT)finance.yahoo.com - July 12 at 10:01 PMClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meetingfinance.yahoo.com - June 9 at 11:20 AMClarus' oral testosterone product Jatenzo gets patent nodseekingalpha.com - May 18 at 5:26 PMClarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)finance.yahoo.com - May 18 at 5:26 PMClarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 16 at 10:23 PMClarus Therapeutics Misses Q1 EPS by 21cinvesting.com - May 16 at 5:23 PMClarus Therapeutics Reports First Quarter 2022 Financial and Operating Resultsfinance.yahoo.com - May 16 at 5:23 PMClarus Therapeutics Q1 2022 Earnings Previewseekingalpha.com - May 13 at 8:23 PMClarus Therapeutics to Report First Quarter 2022 Financial and Operating Resultsfinance.yahoo.com - May 12 at 1:06 PMClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitisfinance.yahoo.com - May 10 at 1:23 PMClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meetingfinance.yahoo.com - May 9 at 10:34 AMClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)finance.yahoo.com - April 28 at 12:42 PMClarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offeringfinance.yahoo.com - April 27 at 4:01 PMWhy Clarus Therapeutics Shares Are Getting Hammereduk.investing.com - April 25 at 3:20 PMYou Ask, We Analyze: What To Watch For In Clarus Therapeutics Stock Following Last Week's Surgemsn.com - April 25 at 3:20 PMClarus Therapeutics nosedives on pricing upsized $30M stock and warrants offeringseekingalpha.com - April 25 at 10:20 AMClarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offeringapnews.com - April 25 at 10:20 AMClarus Therapeutics plunges 22% on equity offeringseekingalpha.com - April 25 at 10:20 AMPre-market Movers: SCYX, DAIO, OMEX, CRSR, GPS…nasdaq.com - April 22 at 8:22 AMClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meetingfinance.yahoo.com - April 19 at 9:47 AMBioMed Momentum: VERU, NMLSF, PHRX, CRXT; Life Sciences Leaders Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autismfinance.yahoo.com - April 14 at 1:26 PMClarus Therapeutics Tops Q4 EPS by 49cuk.investing.com - March 30 at 9:27 PMClarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Resultsmorningstar.com - March 30 at 4:27 PMClarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Resultsfinance.yahoo.com - March 29 at 8:26 PMDLNG, MULN and OCFT among mid-day moversseekingalpha.com - March 27 at 9:39 PMClarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Diseasefinance.yahoo.com - March 16 at 1:30 PMClarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conferencefinance.yahoo.com - March 10 at 1:49 PMClarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patientsfinance.yahoo.com - February 24 at 1:00 PMAntares resubmitted NDA for testosterone replacement therapy Tlando accepted by FDAseekingalpha.com - February 3 at 9:50 AMLipocine announces FDA accepted the marketing application for Tlandoseekingalpha.com - February 3 at 9:50 AMClarus Therapeutics Expects To Initiate In H2 2022, Phase 2 Trial To Provide Once Daily Oral Testosterone Undecanoate To Treat Male Hypogonadismbenzinga.com - January 20 at 12:52 AMClarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officerfinance.yahoo.com - January 18 at 9:34 AMClarus Therapeutics Holdings Inc Shares Close the Week 31.7% Lower - Weekly Wrapnasdaq.com - January 10 at 4:00 PMClarus Therapeutics Holdings Inc Shares Near 52-Week Low - Market Movernasdaq.com - January 9 at 12:55 PMClarus Therapeutics Holdings Inc Shares Fall 10.5% Below Previous 52-Week Low - Market Movernasdaq.com - January 7 at 8:24 AMClarus Therapeutics Holdings Inc Shares Close the Day 10.5% Lower - Daily Wrapnasdaq.com - January 7 at 8:24 AMClarus Therapeutics Holdings Inc (CRXT)investing.com - January 5 at 9:09 PMClarus Therapeutics Announces Closing of Approximately $15 Million Private Placementfinance.yahoo.com - December 7 at 7:25 PMClarus Therapeutics Announces $15 Million Private Placementfinance.yahoo.com - December 3 at 2:30 PMThinking about buying stock in Cumberland Pharmaceuticals, AT&T, Clarus Therapeutics, RLX Technology, or Norwegian Cruise Line?benzinga.com - December 1 at 12:47 AMClarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)finance.yahoo.com - November 30 at 9:24 AMmarketbeat.com - November 23 at 11:28 AMmarketbeat.com - November 23 at 11:19 AMmarketbeat.com - November 23 at 10:59 AM Get Clarus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRXTQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here CRXTQ Media Mentions By Week CRXTQ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRXTQ News Sentiment▼0.000.58▲Average Medical News Sentiment CRXTQ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRXTQ Articles This Week▼00▲CRXTQ Articles Average Week Get Clarus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRXTQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AVXT News CRXM News VECT News TGIFF News FFNTF News ABSCF News ACONW News ACRHF News ACRDF News ADMT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CRXTQ) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithObama’s Forever Term [exposed]Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarus Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
